Neoplasms

All Conditions

Digestive System Diseases

Symptoms and General Pathology

Carcinoma

Carcinoma, Hepatocellular

Recurrence

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Disease Attributes

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Epirubicin

Immunomodulating Agents

Chlorotrianisene

Mitomycins

Mitomycin

Ethiodized Oil

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Alkylating Agents

Transcatheter Arterial Chemoembolization(TACE) treatment:patients will receive lipiodol,Mitomycin (MMC),Epirubicin（EADM） hepatic arterial infusion,3 cycles.

After accepting concurrent TACE treatment,patients will receive 3 cycles of Dendritic Cell -Precision Multiple Antigen T (DC-PMAT) cells treatment.

lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm2 hepatic arterial infusion.Each cycle received one TACE treatment on day 13,34,55.

TACE

DC suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.

Dendritic Cell

lipiodol 10-20ml,hepatic arterial infusion

lipiodol

MMC 8～10mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2, hepatic arterial infusion.

Mitomycin (MMC)

EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2 hepatic arterial infusion.

Epirubicin(EADM)

PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.

Precision Multiple Antigen T Cell

Qijun Qian, PHD

Huajun Jin, PHD

Huajun Jin, phd

Feng Shen, PHD

Zengqiang Qu, PHD

Qian Zhang, PHD

Yao Huang, PHD

Yan Sun, PHD

Fuping Zhou, PHD

Objectives:

The purpose of this study is to evaluate the safety and efficacy of dendritic cell-precision multiple antigen T cells with transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma.

Methods： This study designs a novel therapy using dendritic cell-precision multiple antigen T cells. 60 patients will be enrolled. They are randomly divided into transcatheter arterial chemoembolization group and dendritic cell-precision multiple antigen T cells combined with transcatheter arterial chemoembolization group. Treatments will be performed every 3 weeks with a total of three periods. The mail clinical indicators are Progression-Free-Survival and Overall Survival.

A total of 60 patients may be enrolled over a period of 1-2 years.

Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma

A Controlled Clinic Trial of Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen in Combination With Transcatheter Arterial Chemoembolization in Treating Patients With Advanced Hepatocellular Carcinoma

Quality of life core questionnaire will be used.

Second Military Medical University

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma	NCT02638857	Recurrence Hepa... Advanced Hepato...	TACE Dendritic Cell lipiodol Mitomycin (MMC) Epirubicin(EADM... Precision Multi...	18 Years - 65 Years	Second Military Medical University
Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma	NCT02638857	Recurrence Hepa... Advanced Hepato...	TACE Dendritic Cell lipiodol Mitomycin (MMC) Epirubicin(EADM... Precision Multi...	18 Years - 65 Years	Second Military Medical University

Spots Global Cancer Trial Database for precision multiple antigen t cell